IJCM  Vol.11 No.12 , December 2020
Lymphocytopenia and Neutrophilia Deteriorate at the Lowest Oxygenation Index Timepoint in COVID-19 Patient
Abstract: Objective: Coronavirus disease 2019 (COVID-19) spread throughout the world and caused hundreds of thousands of infected people to death. However, the pathogenesis of severe acute respiratory syndrome coronavirus-2 (SARS COV-2) is poorly understood. The objective of this study is to retrospectively explore the pathogenesis of COVID-19 from clinical laboratory findings, taking disease progression into account. Methods: A single-centered, retrospective study was carried out, which included moderate (n = 76) and severe COVID-19 cases (n = 22). The difference of laboratory findings from blood routine examination and hepatorenal function test were retrospectively evaluated between the state of moderate and severe. The disease progression was indicated by oxygenation index. Results: Age is a risk factor for disease progression from moderate to severe. Lymphocytopenia, neutrophilia, liver and kidney function decreasement occurred in severe patients on admission, compared with moderate patients. Lymphocytopenia and neutrophilia deteriorated at the lowest oxygenation index timepoint in the severe patients. And the oxygenation index was associated with ratio of lymphocyte and neutrophil in COVID-19 patients. Conclusions: Lymphocytopenia and neutrophilia, which deteriorate in the progression of severe patients, are the main pathogenesis of COVID-19. More measures need to be taken to control lymphocytopenia and neutrophilia in severe COVID-19. Oxygenation index presented potentiality as predictor on the progression of COVID-19.
Cite this paper: Xu, Y. , Hong, W. , Wu, G. , Li, W. , Xu, C. , Hu, X. , Zhang, M. , Xu, H. , Wang, E. , Ke, S. and Jin, X. (2020) Lymphocytopenia and Neutrophilia Deteriorate at the Lowest Oxygenation Index Timepoint in COVID-19 Patient. International Journal of Clinical Medicine, 11, 810-822. doi: 10.4236/ijcm.2020.1112060.

[1]   WHO (2020) Coronavirus Disease 2019 (COVID-19) Situation Report.

[2]   WHO (2020) Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease Is Suspected. Interim Guidance. Pediatria i Medycyna Rodzinna, 16, 9-26.

[3]   Xu, X.W., Wu, X.X., Jiang, X.G., Xu, K.J., Ying, L.J., Ma, C.L., et al. (2020) Clinical Findings in a Group of Patients Infected with the 2019 Novel Coronavirus (SARS-Cov-2) Outside of Wuhan, China: Retrospective Case Series. BMJ, 368, m606.

[4]   Glantzounis, G.K., Tsimoyiannis, E.C., Kappas, A.M. and Galaris, D.A. (2005) Uric Acid and Oxidative Stress. Current Pharmaceutical Design, 11, 4145-4151.

[5]   Zhang, B., Zhou, X., Qiu, Y., Song, Y., Feng, F., Feng, J., et al. (2020) Clinical Characteristics of 82 Cases of Death from COVID-19. PLoS ONE, 15, e0235458.

[6]   Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., et al. (2020) Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet, 395, 497-506.

[7]   Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., et al. (2020) Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA, 323, 1061-1069.

[8]   Yan, L., Zhang, H.-T., Goncalves, J., Xiao, Y., Wang, M., Guo, Y., et al. (2020) An Interpretable Mortality Prediction Model for COVID-19 Patients. Nature Machine Intelligence, 2, 283-288.

[9]   Zhao, X.Y., Xu, X.X., Yin, H.S., Hu, Q.M., Xiong, T., Tang, Y.Y., et al. (2020) Clinical Characteristics of Patients with 2019 Coronavirus Disease in a Non-Wuhan Area of Hubei Province, China: A Retrospective Study. BMC Infectious Diseases, 20, 311.

[10]   Zhang, X., Cai, H., Hu, J., Lian, J., Gu, J., Zhang, S., et al. (2020) Epidemiological, Clinical Characteristics of Cases of SARS-CoV-2 Infection with Abnormal Imaging Findings. International Journal of Infectious Diseases, 94, 81-87.

[11]   Ottestad, W., Seim, M. and Maehlen, J.O. (2020) COVID-19 with Silent Hypoxemia. Tidsskr Nor Laegeforen, 140, 1-3.

[12]   Feng, G., Zheng, K.I., Yan, Q.Q., Rios, R.S., Targher, G., Byrne, C.D., et al. (2020) COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. Journal of Clinical and Translational Hepatology, 8, 18-24.

[13]   Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., et al. (2020) Clinical Course and Outcomes of Critically Ill Patients with SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study. The Lancet Respiratory Medicine, 8, 475-481.

[14]   Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., et al. (2020) Clinical and Immunological Features of Severe and Moderate Coronavirus Disease 2019. Journal of Clinical Investigation, 130, 2620-2629.

[15]   Short, K.R., Kroeze, E., Fouchier, R.A.M. and Kuiken, T. (2014) Pathogenesis of Influenza-Induced Acute Respiratory Distress Syndrome. The Lancet Infectious Diseases, 14, 57-69.

[16]   Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., et al. (2020) COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression. The Lancet, 395, 1033-1034.

[17]   Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., et al. (2020) Pathological Findings of COVID-19 Associated with Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine, 8, 420-422.

[18]   Barton, L.M., Duval, E.J., Stroberg, E., Ghosh, S. and Mukhopadhyay, S. (2020) COVID-19 Autopsies, Oklahoma, USA. American Journal of Clinical Pathology, 153, 725-733.

[19]   Liu, Q., Wang, R.S., Qu, G.Q., Wang, Y.Y., Liu, P., Zhu, Y.Z., et al. (2020) Gross Examination Report of a COVID-19 Death Autopsy. Journal of Forensic Medicine, 36, 21-23.

[20]   Liu, Y., Pang, Y., Hu, Z., Wu, M., Wang, C., Feng, Z., et al. (2020) Thymosin Alpha 1 (Talpha1) Reduces the Mortality of Severe COVID-19 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. Clinical Infectious Diseases, 71, 2150-2157.

[21]   Nemeth, T., Sperandio, M. and Mocsai, A. (2020) Neutrophils as Emerging Therapeutic Targets. Nature Reviews Drug Discovery, 19, 253-275.

[22]   Luo, P., Liu, Y., Qiu, L., Liu, X., Liu, D. and Li, J. (2020) Tocilizumab Treatment in COVID-19: A Single Center Experience. Journal of Medical Virology, 92, 814-818.

[23]   Xu, X., Han, M., Li, T., Sun, W., Wang, D., Fu, B., et al. (2020) Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Proceedings of the National Academy of Sciences of the United States of America, 117, 10970-10975.

[24]   Sallard, E., Lescure, F.X., Yazdanpanah, Y., Mentre, F. and Peiffer-Smadja, N. (2020) Type 1 Interferons as a Potential Treatment against COVID-19. Antiviral Research, 178, Article ID: 104791.

[25]   Chu, H., Chan, J.F., Wang, Y., Yuen, T.T., Chai, Y., Hou, Y., et al. (2020) Comparative Replication and Immune Activation Profiles of SARS-CoV-2 and SARS-CoV in Human Lungs: An Ex Vivo Study with Implications for the Pathogenesis of COVID-19. Clinical Infectious Diseases, 71, 1400-1409.

[26]   Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., et al. (2020) SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. Cell, 181, 1016-1035e1019.

[27]   Ye, Q., Wang, B., Mao, J., Fu, J., Shang, S., Shu, Q., et al. (2020) Epidemiological Analysis of COVID-19 and Practical Experience from China. Journal of Medical Virology, 92, 755-769.

[28]   Zhagn, S., Li, D., Chen, H., Zheng, D., Zhou, Y., Chen, B., et al. (2020) Dynamic Inflammatory Response in a Critically Ill COVID-19 Patient Treated with Corticosteroids]. Journal of Zhejiang University. Medical Sciences, 49, 220-226.

[29]   Xie, Y., Cao, S., Dong, H., Li, Q., Chen, E., Zhang, W., et al. (2020) Effect of Regular Intravenous Immunoglobulin Therapy on Prognosis of Severe Pneumonia in Patients with COVID-19. Journal of Infection, 81, 318-356.

[30]   Fowler, A.A., Truwit, J.D., Hite, R.D., Morris, P.E., DeWilde, C., Priday, A., et al. (2019) Effect of Vitamin C Infusion on Organ Failure and Biomarkers of Inflammation and Vascular Injury in Patients with Sepsis and Severe Acute Respiratory Failure: The CITRIS-ALI Randomized Clinical Trial. JAMA, 322, 1261-1270.